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Abstract
Background: The main aim of this study was to compare the safety and efficacy of IR MPH
administered three times daily to those of once daily OROS-MPH.
Methods: Subjects were outpatient adults satisfying full diagnostic criteria for DSM-IV ADHD
between 19 and 60 years of age. Data from two independently conducted 6-week placebo
controlled, randomized clinical trials of IR-MPH (tid) and of OROS-MPH were pooled to create
three study groups: Placebo (N = 116), IR-MPH (tid) (N = 102) and OROS-MPH (N = 67).
Results: Eight-five percent (N = 99) of placebo treated subjects, 77% (N = 79) of the IR-MPH (tid)
treated subjects, and 82% (N = 55) of the OROS-MPH treated subjects completed the 6-week trial.
Total daily doses at endpoint were 80.9 ± 31.9 mg, 74.8 ± 26.2 mg, and 95.4 ± 26.3 mg in the
OROS-MPH, IR-MPH (tid), and placebo groups, respectively. At endpoint, 66% (N = 44) of subjects
receiving OROS-MPH and 70% (N = 71) of subjects receiving IR-MPH (tid) were considered
responders compared with 31% (N = 36) on placebo.
Conclusion:  Comparison of data from two similarly designed, large, randomized, placebo-
controlled, trials, showed that equipotent daily doses of once daily OROS-MPH had similar efficacy
to that of TID administered IR MPH.
Trial Registration: The trial of OROS-MPH was registered at clinicaltrials.gov, number
NCT00181571.
Background
Attention deficit hyperactivity disorder (ADHD) is a per-
sistent disorder associated with high levels of morbidity
and disability across the lifecycle. Although long concep-
tualized as a pediatric disorder, it is now estimated to
affect between 3%–5% of adults in this country [1,2]. The
extant literature documents several similarities between
adult and pediatric ADHD in terms of psychiatric comor-
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bidity and neuropsychological deficits, as well as a neural
and genetic underpinning that supports the syndromatic
continuity of ADHD across the lifecycle [3]. Recent work
has also documented the severe functional impairments
associated with ADHD including educational and occupa-
tional under attainment, driving accidents, addictive
behaviors and a wide range of interpersonal deficits
adversely impacting all aspects of life [4] supporting the
need for the identification of safe and effective treatments
for this disorder in adults.
While methylphenidate (MPH) remains one of the lead-
ing pharmacological treatments of pediatric ADHD, there
is a limited literature on its safety and efficacy in the treat-
ment of adults with ADHD. In contrast to equivocal
results observed in early studies that used daily doses of
approximately 0.5 mg/kg of immediate release methyl-
phenidate (IR MPH) [5-9], clearer patterns of response
were documented in studies using doses of approximately
1 mg kg of IR-MPH [10,11]. These findings suggest that
MPH is effective in the treatment of adults with ADHD
when used in weight adjusted doses equipotent to those
used in pediatrics.
Results from a recent, large randomized, six week, place-
bocontrolled clinical trial documented that osmotic
release methylphenidate (OROS-MPH) at daily average
doses of 1 mg/kg/day was also highly effective and well
tolerated in the treatment of adults with ADHD [12].
Since Spencer et al [11] administered MPH three times
daily and the long acting formulation of OROS-MPH was
designed to provide day-long coverage, these results sug-
gest that a key component of efficacy observed in these
studies may also be day long pharmacological coverage.
Although OROS-MPH was designed to mimic the phar-
macokinetic profile of IR MPH administered three times
daily, is unclear if these two formulations of MPH are
equally tolerated and effective since there have been no
head to head comparisons conducted.
In the absence of randomized head to head comparisons,
existing studies that used OROS and IR formulations of
MPH could be compared if they employed similar meth-
odology. We have conducted two six week, randomized,
placebo-controlled studies of OROS-MPH and IR MPH
that used nearly identical dosing and assessment method-
ology. The main aim of this study was to compare the
safety and efficacy of equipotent doses of IR MPH admin-
istered TID to those of once daily OROS-MPH. To this end
we used data from two similarly designed, large, rand-
omized, placebo-controlled, six week trials of IR and
OROS-MPH in adults with DSM-IV ADHD [11,12]. We
hypothesized that once daily OROS-MPH would show
similar efficacy and tolerability to that of IR-MPH admin-
istered three times a day.
Methods
Subjects
Subjects in both studies were outpatient adults with
ADHD between 19 and 60 years of age. To be included,
subjects had to satisfy full diagnostic criteria for DSM-IV
ADHD based on clinical assessment and confirmed by
structured diagnostic interview. There was no overlap in
participation between the study samples. We excluded
potential subjects if they had clinically significant chronic
medical conditions, abnormal baseline laboratory values,
I.Q. <80, delirium, dementia, or amnestic disorders, other
clinically unstable psychiatric conditions (i.e., bipolar dis-
order, psychosis, suicidality), drug or alcohol abuse or
dependence within the six months preceding the study, or
previous adequate trial of methylphenidate. We also
excluded pregnant or nursing females. The human
research committee of the institutional review board
(IRB) approved these studies and all subjects completed a
written informed consent.
Procedures
Randomized Trial of IR-MPH (tid) [11]
This was a double-blind, randomized, 6 week, placebo-
controlled, parallel design study of MPH in the treatment
of adult ADHD. Patients were randomized to MPH or pla-
cebo at a ratio of 2.5:1. Weekly supplies of MPH or pla-
cebo were dispensed by the pharmacy in identically
appearing 5 and10 mg capsules. Study physicians pre-
scribed medication under double blind conditions in
three times per day dosing (7:30 am, noon and 5 pm).
Study medication was titrated (forced titration) up to 0.5
mg/kg/day by weekone, 0.75 mg/kg/day by week two and
1.0 mg/kg/day by week three, in TID dosing, unless
adverse effects emerged. The dose could have been
increased to a maximum of 1.3 mg/kg by weeks 5 and 6 if
efficacy was partial and treatment was well tolerated.
Other psychoactive medications were not permitted dur-
ing the protocol.
Randomized Trial of OROS-MPH [12]
This was a double blind, randomized, 6-week, placebo-
controlled, parallel design study of OROS-MPH. Patients
were randomized to OROS-MPH or placebo at a ratio of
1:1. Medication was titrated to optimal response (a maxi-
mum daily dose of 1.3 mg/kg; initial dose of 36 mg). Dur-
ing titration to optimal response, dose was increased by
36 mg/day for only those subjects who failed to attain an
a priori definition of improvement defined by a clinical
global impressions scale-improvement (CGI-Improve-
ment) score of 1 or 2 and a reduction in the Adult ADHD
Investigator Symptom Rating Scale (AISRS) score larger
than 30%) and who did not experience adverse effects. All
doses of OROS-MPH and placebo were delivered in iden-
tically appearing tablets.BMC Psychiatry 2007, 7:49 http://www.biomedcentral.com/1471-244X/7/49
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Assessment
To assess inclusion and exclusion criteria, all subjects
underwent a comprehensive clinical assessment which
included a psychiatric evaluation by a board certified psy-
chiatrist, structured diagnostic interview, medical history,
vital signs, and laboratory assessments (liver function
tests, complete blood count, and electrocardiogram). The
structured diagnostic interview used was the Structured
Clinical Interview for DSM-IV (SCID) [13], supplemented
for childhood disorders by modules (DSM-IV ADHD and
conduct disorder) from the Kiddie SADSE (Epidemiologic
Version). [14]. This interview was selected because it diag-
noses both lifetime and current month psychopathology
and has been used extensively in clinical and research set-
tings [11,15].
To have been given a full diagnosis of adult ADHD, the
subject must have: a)met full DSMIVR criteria (at least 6
of 9 symptoms) for inattentive and/or hyperactive/impul-
sive subtypes [16] by the age of seven as well as within the
past month (i.e. ADHD-IA, ADHD-HI and ADHD-C sub-
jects were enrolled); b)described a chronic course of
ADHD symptomatology from childhood to adulthood
and c) endorsed a moderate or severe level of impairment
attributed to the ADHD symptoms.
Overall severity and change in severity of ADHD was
assessed with the Clinical Global Impression Scale (CGI)
[17]. The CGI includes Global Severity (1 = not ill, to 7 =
extremely ill) and Global Improvement (1 = very much
improved, to 7 = very much worse) Scales. The Adult
ADHD Investigator System report Scale (AISRS) [18] was
used to assess each of the 18 individual criteria symptoms
of ADHD in DSMIV on a severity grid (0 = not present; 3
= severe; overall minimum score = 0; maximum score =
54). To assess symptoms of depression and anxiety, we
used the 17-item Hamilton Depression Scale (HAM-D,
minimum = 0; max = 52) [19] and the Hamilton Anxiety
Scale (HAM-A, minimum = 0; max = 56)[20]. A global
measure of psychosocial functioning (global assessment
of functioning (GAF) scale) was rated according to guide-
lines in DSM-IV [21]. Adverse events were elicited by
spontaneous reports through open-ended questions at
each visit. Weight and vital signs were obtained at each
visit and an EKG was performed at baseline and endpoint.
Both raters and subjects were blind to treatment assign-
ment.
Statistical Analysis
Analyses were intention to treat (ITT) with the exception
that subjects must have been assessed on drug or placebo
for at least one week (92% [11] and 95% [12] of rand-
omized returned for at least 1 assessment). A mixed-
effects model repeated measures approach was used to
account for missing data in our longitudinal assessments
of safety (i.e. weight and vital signs) and efficacy. Models
assessing symptom improvement of the primary measure
of outcome (AISRS score) were adjusted for any demo-
graphic or clinical differences at baseline between the
groups and baseline AISRS score. Omnibus and pair wise
comparisons were made with post estimation Wald tests
such that χ2 statistics are reported for continuous data.
Continuous and categorical data were tested with ANOVA
and Pearson's χ2, respectively for non-longitudinal data
(i.e. demographics at baseline, prevalence of adverse
effects or response at endpoint, etc). Statistical signifi-
cance was determined at p < 0.05. For simplicity of expo-
sition, placebo subjects from both studies were pooled
into a single placebo group. Thus, three groups were com-
pared: Placebo (N = 116), IR-MPH (tid) (N = 102) and
OROS-MPH (N = 67).
Results
Clinical and demographic characteristics are presented in
Table 1. Although there were small but statistically signif-
icant differences in age between the groups (statistically
significant for OROS-MPH versus placebo), each of the
three groups were in their mid thirties, on average. There
were no statistically significant differences in gender,
ADHD age at onset, number of symptoms, or clinical
impression of severity at baseline.
At baseline, there were small statistically significant but
not clinically meaningful differences in global assessment
of functioning and ratings of anxiety that were slightly
worse in the OROS-MPH than in the IR MPH groups
(Table 1). Also, there was a small but significant difference
in the AISRS score between the three groups (F(2.282) =
4.1, p = 0.02) that was accounted for by a difference
between the OROS-MPH (30.1 ± 5.9) and the placebo
(32.1 ± 7.9) subjects (Figure 1).
There were no differences in dose at endpoint between IR-
MPH (tid) and OROS-MPH (0.97 ± 0.21 mg/kg versus
0.99 ± 0.32 mg/kg; p = 0.09) but both were statistically
significantly lower than placebo (1.15 ± 0.21 mg/kg; p =
0.001). Total daily doses at endpoint were 80.9 ± 31.9 mg,
74.8 ± 26.2 mg, and 95.4 ± 26.3 mg in the OROS-MPH,
IR-MPH (tid), and placebo groups, respectively.
Eight-five percent (N = 98) of placebo treated subjects,
75% (N = 76) of the IR-MPH (tid) treated subjects, and
81% (N = 54) of the OROS-MPH treated subjects com-
pleted the 6-week trial (χ2
(2) = 2.3, p = 0.3). In placebo, IR-
MPH (tid) and OROS-MPH subjects the reasons for drop-
out were: adverse effects (N = 5, N = 14, and N = 9, respec-
tively), lost to follow-up (N = 3, N = 3, and N = 4,
respectively), procedural/lack of compliance (N = 6, N = 9
and N = 0, respectively), and lack of effect (N = 4, N = 0,
and N = 0, respectively).BMC Psychiatry 2007, 7:49 http://www.biomedcentral.com/1471-244X/7/49
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Adjusting for baseline AISRS value, there were statistically
significant treatment effects compared to placebo for both
the IR-MPH (tid) (Wald χ2
(6) = 40.9, p < 0.0001) and the
OROS-MPH (Wald χ2
(6) = 23.7, p = 0.0006) groups. There
was not a statistically (Wald χ2
(6) = 7.8, p = 0.3) or clini-
cally significant difference between the IR-MPH (tid) and
OROS-MPH treated subjects (Figure 1).
The rate of improvement according to the psychiatrist
rated clinical global impression (CGI-I) for ADHD was
statistically significantly higher for both IR-MPH (tid)
(χ2
(1) = 27.7, p < 0.001) and OROS-MPH (χ2
(1) = 21.2, p
< 0.001) groups compared with placebo (Figure 2), and
there were no statistically (χ2
(1) = 0.008, p = 0.9) or clini-
cally significant differences between the two formulations
of MPH. Forty percent (N = 46), 80% (N = 80), and 69%
(N = 46) of the placebo, IR-MPH (tid) and OROS-MPH
groups, respectively attained a 30% reduction of baseline
Clinical Ratings of Improvement Figure 2
Clinical Ratings of Improvement.
Table 1: Demographic and Clinical Characteristics at Baseline
Placebo N = 116 IR-MPH (tid) N = 102 OROS-MPH N = 67
mean ± sd/N (%) mean ± sd/N (%) mean ± sd/N (%) Omnibus Statistic
Age (years) 38.5 ± 9.1 35.7 ± 9.8 32.7 ± 18.5 * F(2,282) = 5.0, p = 0.007
Sex (male) 58 (50) 60 (59) 38 (57) χ2
(2) = 1.8, p = 0.4
Weight (kg) 82.9 ± 18.9 79.9 ± 15.8 84.1 ± 20.1 F(2,282) = 1.3, p = 0.3
ADHD
Onset (years) 5.0 ± 2.9 6.3 ± 6.7 5.2 ± 2.2 F(2,253) = 2.0, p = 0.1
Symptoms (lifetime) 14.3 ± 2.8 13.5 ± 3.4 14.4 ± 2.7 F(2,248) = 4.3, p = 0.1
Symptoms (Current) 12.1 ± 3.7 11.5 ± 3.9 12.2 ± 2.9 F(2,248) = 2.0, p = 0.4
CGI Severity
Mild 1 (1) 1 (1) 1 (1) χ2
(6) = 9.6, p = 0.1
Moderate 52 (45) 31 (30) 27 (40)
Marked 53 (46) 60 (59) 38 (57)
Severe 10 (9) 10 (10) 1 (1)
GAF
Past (worst) 52.2 ± 5.6 52.3 ± 5.9 51.4 ± 4.7 F(2,259) = 0.6, p = 0.5
Current 59.0 ± 4.9 59.9 ± 5.0 57.8 ± 4.2$ F(2,259) = 4.1, p = 0.02
HAM-A 4.6 ± 3.9 5.8 ± 4.8 4.4 ± 3.8 F(2,281) = 3.2, p = 0.04
HAM-D 4.4 ± 4.5 5.1 ± 5.3 4.8 ± 4.7 F(2.282) = 0.6, p = 0.6
*, p < 0.05 versus Placebo, $, p < 0.05 versus IR-MPH (tid).
Clinical Ratings of ADHD Symptoms Figure 1
Clinical Ratings of ADHD Symptoms.BMC Psychiatry 2007, 7:49 http://www.biomedcentral.com/1471-244X/7/49
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AISRS scores at endpoint. Both the IR-MPH (tid) and the
OROS-MPH groups were statistically significantly more
likely to have a 30% reduction in symptoms than placebo
(p < 0.001) and were not different from one another (p =
0.1).
At endpoint, 66% (N = 44) of subjects receiving OROS-
MPH and 70% (N = 71) of subjects receiving IR-MPH
(tid) were considered responders compared with 31% (N
= 36) on placebo (χ2(2) = 38.1, p < 0.001), using our a pri-
ori definition of response of much or very much improved
on the CGI-I plus more than a 30% reduction in symp-
toms on the AISRS. Both active medication groups were
statistically significantly more likely to demonstrate this
level of improvement compared with placebo (p < 0.001)
but not when compared to one another (p = 0.6).
The rate of adverse effects reported over the study period
is presented in Table 2. Both the IR-MPH (tid) and the
OROS-MPH treated subjects were more likely to report
dry mouth, decreased appetite, sleep difficulties and
moodiness than were subjects treated with placebo (Table
2). There was a statistically significant greater weight loss
in the IR-MPH (tid) (-2.1 ± 2.4 kg, p < 0.001) and the
OROS-MPH groups (-2.8 ± 1.9 kg, p < 0.001) than in the
placebo group(0.02 ± 1.7 kg); differences in weight loss
between OROS-MPH and IR-MPH (tid) were small but
statistically significant (p = 0.03). In addition subjects
treated with OROS-MPH were more likely than subjects
treated with IR-MPH (tid) to report having dry mouth and
decreased appetite (Table 2). Complaints of GI difficulties
were statistically significantly elevated in the OROS-MPH
subjects only.
There were no serious adverse events reported. Specific
adverse effects leading to drop out in the placebo group
were irritability (N = 1), fatigue (N = 1), increased pulse/
racing heart (N = 1) and elevated blood pressure (N = 2).
Adverse effects leading to dropout in the IR-MPH subjects
were jitteriness (N = 2), irritability (N = 2), depression, (N
= 1), anxiety (N = 1), over-focus (N = 1), headache (N =
1), insomnia (N = 1), and elevated blood pressure (N = 5).
Adverse effects leading to dropout in the OROS-MPH
groups were jitteriness (N = 1), irritability (N = 3), depres-
sion (N = 1), anxiety (N = 1), increased pulse/racing heart
(N = 2) and elevated blood pressure (N = 1).
Changes from baseline to endpoint on cardiac measures
are presented in Table 3. As expected, there were small but
statistically significant differences in diastolic blood pres-
sure and pulse between both active treatment groups and
placebo subjects. There were no differences between the
IR-MPH (tid) and the OROS-MPH groups with the excep-
tion of a smaller increase in pulse in OROS-MPH group
that, although statistically significant (p = 0.049), would
be of limited clinical significance. Outliers analysis of car-
diovascular data revealed that significantly more subjects
treated with OROS-MPH and IR-MPH (tid) attained clin-
ically significant elevated heart rate (>100 bpm: 6 (9%)
and 3 (3%) vs 1 (1%) respectively, χ2
(2) = 8.5, p = 0.02;
maximum value observed was 114 bpm). Other cardio-
vascular outliers were not significantly more likely to
occur in subjects treated with active medication than with
placebo: systolic blood pressure (>140 mmHg: 5 (8%)
and 14 (14%) vs. 6 (5%), χ2
(2) = 5.5, p = 0.06; maximum
value observed was 156 mmHg), diastolic blood pressure
(>90 mmHg: 2 (3%) and 8 (8%) vs. 3 (3%), χ2
(1) = 4.1, p
= 0.1; maximum value observed was 102), or QTC inter-
val (>460 msecs: 1 (2%) and 1 (2%) vs. 2 (2%), χ2
(1) = 0.1,
p = 0.9; maximum value observed was 488 msecs). For
none of these clinical outliers was the difference between
IR-MPH (tid) and OROS-MPH statistically significant.
Discussion
Comparison of data from two similarly designed, large,
randomized, placebo-controlled, 6-week trials of IR and
OROS-MPH in adults with DSM-IV ADHD, showed that
once daily OROS-MPH had similar efficacy and tolerabil-
ity to that of equipotent daily doses of IR-MPH adminis-
tered three times per day. These results confirmed the
study hypothesis that once daily OROS-MPH is as effec-
tive as three times daily IR MPH at similar doses. The find-
Table 2: Adverse Effects
Placebo N = 116 IR-MPH (tid) N = 102 OROS-MPH N = 67
N (%) N (%) N (%) Omnibus Statistic
Dry Mouth 5 (4) 22 (22) * 25 (37)*,$ χ2
(2) = 32.2, p < 0.001
Headache 30 (26) 22 (22) 24 (36) χ2
(2) = 4.2, p = 0.1
Decreased Appetite 4 (3) 11 (11) * 24 (36)*,$ χ2
(2) = 38.8, p < 0.001
GI Complaints 13 (11) 17 (17) 20 (29)*,$ χ2
(2) = 10.3, p = 0.006
Sleep Problems 6 (5) 14 (14) * 14 (21) * χ2
(2) = 10.5, p = 0.005
Moodiness 7 (6) 15 (15) * 12 (18) * χ2
(2) = 6.9, p = 0.03
Aches and Pains 13 (11) 7 (7) 9 (13) χ2
(2) = 2.1, p = 0.3
*, p < 0.05 versus Placebo, $, p < 0.05 versus IR-MPH (tid)BMC Psychiatry 2007, 7:49 http://www.biomedcentral.com/1471-244X/7/49
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ing that the same daily dose of once daily OROS-MPH was
as effective as that of IR-MPH (tid) is consistent with the
pharmacokinetic profile of OROS-MPH that was formu-
lated to deliver three doses of IR MPH across the day with
once daily administration.
The magnitude of response observed in this study is con-
sistent with results reported in over 250 controlled trials
of stimulants in pediatric ADHD using similar weight cor-
rected daily doses of 1 mg/kg/day. Moreover, the response
rate of 70% observed for both formulations of MPH in
adults with ADHD at daily doses of 1 mg/kg are much
higher than the average 52% response rate reported in
early studies of MPH using average daily doses of 0.5 mg/
kg [5-9]. Taken together, these results support the hypoth-
esis that daily doses of 1 mg/kg/day are needed to attain a
robust response to MPH in the treatment of adults with
ADHD.
Despite the relatively high daily doses of MPH used, both
formulations of MPH were well tolerated as manifested in
the high completion rate (~ 80% for both formulations)
and absence of serious adverse events. While subjects
treated with OROS-MPH formulation more commonly
reported dry mouth, decreased appetite, and GI com-
plaints than subjects treated with IR-MPH (tid), only 14%
of each group dropped from the study due to adverse
effects. Treatment with both formulations of MPH was
associated with similarly small but statistically significant
effects in diastolic blood pressure and pulse relative to
placebo. Although abnormal values in cardiovascular
parameters (maximum values observed were 114 bpm for
heart rate, 156 mmHg for systolic blood pressure, 102
mmHg for diastolic blood pressure, and 488 msecs for
QTc interval) were not associated with medical complica-
tions in this study, adults with ADHD should be moni-
tored for changes in blood pressure and weight loss when
receiving treatment with MPH.
The documentation that once daily OROS-MPH is as
effective as IR MPH administered three times daily has
important clinical implications. Because adults with
ADHD tend to be forgetful, once daily administration of
OROS-MPH may lead to better compliance. Also, since
the delivery of MPH via OROS is gradual and the MPH
cannot be as easily extracted from the OROS tablet this
formulation has a lower abuse potential than IR-MPH.
This is so because the abuse potential of MPH is thought
to be due to the rapid onset of blockade of the presynaptic
dopamine transporter (DAT) in the brain [22]. Thus, the
Table 3: Cardiac Parameters and Baseline and Endpoint
Placebo N = 116 IR-MPH (tid) N = 102 OROS-MPH N = 67
mean ± sd mean ± sd mean ± sd Omnibus Statistic
Systolic Blood Pressure
Baseline 121.4 ± 13.7 125.6 ± 13.3 119.2 ± 13.2
Endpoint 120.3 ± 13.0 127.5 ± 12.7 122.6 ± 11.9
Change -1.2 ± 12.3 2.0 ± 12.6 3.5 ± 11.8 χ2
(2) = 6.7, p = 0.03
Diastolic Blood 
Pressure
Baseline 71.3 ± 10.5 75.1 ± 9.6 68.6 ± 8.9
Endpoint 69.8 ± 10.0 77.3 ± 9.2 72.8 ± 9.3
Change -1.5 ± 8.4 2.1 ± 8.8 * 4.0 ± 8.5 * χ2
(2) = 19.9, p < 0.0001
Pulse
Baseline 76.2 ± 10.9 76.5 ± 12.5 78.2 ± 11.6
Endpoint 71.5 ± 10.9 82.3 ± 12.7 82.9 ± 12.6
Change -4.8 ± 11.7 5.9 ± 12.9* 4.5 ± 10.5*,$ χ2
(2) = 27.9, p < 0.0001
PR Interval
Baseline 153.2 ± 18.7 151.3 ± 25.8 151.3 ± 18.3
Endpoint 151.8 ± 17.8 147.9 ± 20.4 147.9 ± 21.1
Change -1.1 ± 13.7 -2.5 ± 11.8 -1.2 ± 11.3 χ2
(2) = 0.6, p = 0.8
QRS Interval
Baseline 87.5 ± 10.9 90.1 ± 12.8 93.3 ± 9.9
Endpoint 88.1 ± 10.4 87.8 ± 10.9 91.5 ± 11.3
Change 0.5 ± 8.6 -1.2 ± 9.7 -1.2 ± 5.8 χ2
(2) = 3.1, p = 0.2
QTc Interval@
Baseline 413.4 ± 18.0 417.1 ± 19.8 412.5 ± 15.6
Endpoint 413.6 ± 16.3 420.9 ± 18.4 414.5 ± 18.8
Change 0.5 ± 18.4 6.1 ± 16.0 1.9 ± 15.7 χ2
(2) = 2.7, p = 0.3
*, p < 0.05 versus Placebo, $, p < 0.05 versus IR-MPH (tid), @, Bazzett's CorrectionBMC Psychiatry 2007, 7:49 http://www.biomedcentral.com/1471-244X/7/49
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more gradual rise of plasma MPH concentration with the
OROS formulation of MPH could lead to a slower onset
of blockade of the presynaptic DAT and therefore a lower
risk for detection of euphoria [22]. Spencer et al [23] com-
pared the relationship between peripheral and central
pharmacokinetic properties of IR and OROS-MPH and
their impact on abuse liability potential using C-11 altro-
pane and positron emission tomography (PET) and found
further support of this hypothesis.
The results of this study should be viewed in light of meth-
odological limitations. Our criteria for ADHD were some-
what stricter than that DSM-IV. We required full
childhood onset, whereas DSM-IV only requires some sig-
nificant symptoms in childhood. The diagnosis of ADHD
and assessment of ADHD symptoms also relied on self-
report. Although the usefulness of self reports of ADHD
symptoms are limited in pediatric samples, there is evi-
dence that self reports of adults with ADHD correspond
very well to corroborating histories provided by parents
and spouses [24]. Also, assessment of adverse effects
relied on spontaneous reports and such open-ended ques-
tioning of adverse events limits the precision of character-
ization that may be found in structured rating scales.
While the current study is reassuring, strong inferences
about tolerability and safety that require a much larger
sample size to fully assess the occurrences of rare adverse
events. Future work that can directly assess any improve-
ments in treatment compliance associated with once-daily
treatments for ADHD are also needed.
Conclusion
Despite these limitations, comparison of data from two
similarly designed, large, randomized, placebo-controlled
trials showed that OROS-MPH has similar efficacy and
tolerability as that of IR-MPH administered three times
per day. These results indicate that MPH is highly effective
for the treatment of adults with ADHD when delivered in
appropriate doses and dosed across the day. More work is
needed to evaluate whether these short-term benefits
extend to the long-term.
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